Ginkgo Bioworks: 10% owner Canton Barry sold 41,172 shares

What happened

• Canton Barry, listed as a 10% owner, exercised or converted derivatives on Oct 16, 2026, acquiring a total of 76,462 shares (26,802; 9,762; 29,279; 10,619). On Oct 19, 2026, he sold 18,803 shares for $190,719 and 22,369 shares for $226,889, a total sale of 41,172 shares for $417,608. The exercise/conversion entries show N/A for per-share price.

Key details

• Transaction dates and prices:
  • Oct 16, 2026: exercised/converted derivative (M) for 26,802; 9,762; 29,279; and 10,619 shares (total 76,462 shares), price N/A.
  • Oct 19, 2026: open market sales (S) of 18,803 shares @ $10.14 for $190,719 and 22,369 shares @ $10.14 for $226,889.
• Shares owned after the transactions: not reported in the provided filing extract.
• Relevant footnotes from the filing:
  • F1: each RSU represents a contingent right to receive one share of Class A common stock.
  • F2: the shares sold were to cover tax withholding obligations in connection with vesting (sell-to-cover), and such sales do not represent discretionary trades by the reporting person.
  • F3: certain RSUs were approved Jul 28, 2026; 75% vested on Oct 16, 2026 and 25% will vest on Jan 21, 2027.
  • F4: other RSUs were approved Jul 28, 2026 and vest in equal quarterly installments over the next 12 quarters.
• Filing timeliness: filing date Oct 21, 2026; timeliness (late or on time) is not indicated in the provided extract.

Why it may matter

• The filing shows derivative exercises/conversions on Oct 16, 2026 and subsequent sales on Oct 19, 2026; the sales were identified as sell-to-cover for tax withholding.
• Canton Barry is reported as a 10% owner (a large holder rather than an officer or director in this filing).
• A filing does not show why the insider traded or why the company acted.